Loading...
Optimizing Early “Go/No Go” Decisions in CNS Drug Development
Go/No Go decisions concerning development of any single compound determine investment in increasingly costly studies from Phase 1–3. Such decisions are problematic for CNS drug development where the variety of molecular targets in the brain have stimulated decades of studies without major therapeuti...
Na minha lista:
| Udgivet i: | Expert Rev Clin Pharmacol |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4648539/ https://ncbi.nlm.nih.gov/pubmed/25537256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17512433.2015.991715 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|